It appears you don't have support to open PDFs in this web browser. To view this file, Open with your PDF reader
Abstract
Translation and transcription are frequently dysregulated in cancer. These two processes are generally regulated by distinct sets of factors. The CBFB gene, which encodes a transcription factor, has recently emerged as a highly mutated driver in a variety of human cancers including breast cancer. Here we report a noncanonical role of CBFB in translation regulation. RNA immunoprecipitation followed by deep sequencing (RIP-seq) reveals that cytoplasmic CBFB binds to hundreds of transcripts and regulates their translation. CBFB binds to mRNAs via hnRNPK and enhances translation through eIF4B, a general translation initiation factor. Interestingly, the RUNX1 mRNA, which encodes the transcriptional partner of CBFB, is bound and translationally regulated by CBFB. Furthermore, nuclear CBFB/RUNX1 complex transcriptionally represses the oncogenic NOTCH signaling pathway in breast cancer. Thus, our data reveal an unexpected function of CBFB in translation regulation and propose that breast cancer cells evade translation and transcription surveillance simultaneously through downregulating CBFB.
CBFB is highly mutated in breast cancers and is known to interact with RUNX proteins to regulate transcription. Here, the authors describe a non-canonical role of CBFB in translation regulation in which it binds to mRNAs through hnRNPK, facilitating translation by eIF4B.
You have requested "on-the-fly" machine translation of selected content from our databases. This functionality is provided solely for your convenience and is in no way intended to replace human translation. Show full disclaimer
Neither ProQuest nor its licensors make any representations or warranties with respect to the translations. The translations are automatically generated "AS IS" and "AS AVAILABLE" and are not retained in our systems. PROQUEST AND ITS LICENSORS SPECIFICALLY DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING WITHOUT LIMITATION, ANY WARRANTIES FOR AVAILABILITY, ACCURACY, TIMELINESS, COMPLETENESS, NON-INFRINGMENT, MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. Your use of the translations is subject to all use restrictions contained in your Electronic Products License Agreement and by using the translation functionality you agree to forgo any and all claims against ProQuest or its licensors for your use of the translation functionality and any output derived there from. Hide full disclaimer
Details



1 Center for Cancer Research, National Cancer Institute, National Institutes of Health, Cancer and Stem Cell Epigenetics Section, Laboratory of Cancer Biology and Genetics, Bethesda, USA (GRID:grid.417768.b) (ISNI:0000 0004 0483 9129)
2 Center for Cancer Research, National Cancer Institute, National Institutes of Health, Cancer Biology of TGF-beta Section, Laboratory of Cancer Biology and Genetics, Bethesda, USA (GRID:grid.417768.b) (ISNI:0000 0004 0483 9129)
3 National Cancer Institute, National Institutes of Health, Laboratory of Receptor Biology & Gene Expression, Center for Cancer Research, Bethesda, USA (GRID:grid.48336.3a) (ISNI:0000 0004 1936 8075)
4 Center for Cancer Research, National Cancer Institute, National Institutes of Health, High-Dimension Data Analysis Group, Laboratory of Cancer Biology and Genetics, Bethesda, USA (GRID:grid.417768.b) (ISNI:0000 0004 0483 9129)
5 Center for Cancer Research, National Cancer Institute, National Institutes of Health, In Vitro Pathogenesis Section, Laboratory of Cancer Biology and Genetics, Bethesda, USA (GRID:grid.417768.b) (ISNI:0000 0004 0483 9129)
6 Center for Cancer Research, National Cancer Institute, National Institutes of Health, Cancer Genetics Section, Laboratory of Cancer Biology and Genetics, Bethesda, USA (GRID:grid.417768.b) (ISNI:0000 0004 0483 9129)
7 Lung, and Blood Institute, National Institutes of Health, Transgenic Core, National Heart, Bethesda, USA (GRID:grid.94365.3d) (ISNI:0000 0001 2297 5165)